THERAPY DOSSIER · th-663a5aa0ed42

Bifendate derivative 7k (dimethyl biphenyl dicarboxylate bearing thiazolidine-2,4-dione)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22019226 ↗2011Reported benefit

Synthesis and biological evaluation of novel dimethyl[1,1'-biphenyl]-2,2'-dicarboxylate derivatives containing thiazolidine-2,4-dione for the treatment of concanavalin A-induced acute liver injury of BALB/c mice.

MouseChemical/toxinBALB/c

Model: Concanavalin A-induced immune-mediated acute liver injury; carrageenan-induced paw oedema

Compound 7k dose-dependently inhibited paw oedema and lowered serum ALT and AST in concanavalin A-induced hepatitis, with histopathology indicating better hepatoprotection than bifendate.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…